iBio, Inc. (IBIO) News
Follow iBio, Inc. (IBIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
HC Wainwright initiates iBio coverage with Buy rating, $7 target
HC Wainwright & Co. initiated coverage of iBio with a Buy rating and a $7.00 price target, implying 493.2% upside versus the Sep 16 close of $1.18.
EQUITY | Sep 17, 2026, 10:24 AM UTC
L
iBio updates corporate presentation, details pipeline milestones and $88M cash runway
iBio updated its corporate presentation highlighting next—gen obesity antibody programs, near—term IND/clinical milestones and $88.0M cash on hand.Key Highlights:Original SEC Filing: iBio, Inc. [ IBIO ] - 8-K - Sep. 14,
REGULATION | Sep 14, 2026, 08:24 PM UTC
L
IBIO touts long-acting antibody pipeline for obesity and muscle loss
IBIO highlighted a pipeline of long-acting antibodies aimed at obesity and related cardiometabolic disease, emphasizing quality weight loss and muscle preservation. Key assets cited include an Activin E antibody and a my
EQUITY | Sep 08, 2026, 10:10 PM UTC
L
IBIO long-acting antibodies advance toward obesity and muscle milestones
IBIO is advancing long-acting antibody programs for obesity and related diseases, targeting quality and durability of weight loss. Lead programs include pathways such as Activin E and myostatin, with milestones expected
EQUITY | Sep 08, 2026, 09:33 PM UTC
L
iBio to participate in 2026 Wells Fargo Healthcare conference
iBio says it will participate in the 2026 Wells Fargo Annual Healthcare Conference.
EQUITY | Sep 01, 2026, 08:30 PM UTC
L
iBio reports FY 2026 revenue, loss
iBio reported FY 2026 revenue of $100K, net income of ($33.04M) and EPS of ($0.32) in its 10-K summary.
EARNINGS | Aug 28, 2026, 12:46 PM UTC
L
IBIO advances AI obesity antibody pipeline to clinic
IBIO’s AI-driven obesity antibody pipeline advanced to clinic as net loss rose, with liquidity still described as strong.
EQUITY | Aug 28, 2026, 12:40 PM UTC
L
IBIO advances clinical pipeline, extends cash runway to fiscal 2028
IBIO reports an advanced clinical pipeline and secured funding that extends its cash runway into fiscal 2028.
EQUITY | Aug 28, 2026, 12:38 PM UTC
L
iBio reports FY2026 net loss and revenue with $88.0M cash
iBio reported FY2026 net loss of $33.0M and revenue of $0.1M. Cash and investments totaled $88.0M.
EARNINGS | Aug 28, 2026, 12:34 PM UTC
M
iBio reports fiscal year 2026 financial results and corporate update
iBio (IBIO) reported fiscal year 2026 financial results and a corporate update.
EQUITY | Aug 28, 2026, 11:07 AM UTC
L
iBio Appoints Molly Carr Chief Medical Officer
iBio appoints new Chief Medical Officer
EQUITY | Aug 04, 2026, 11:00 AM UTC
L
iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulat
iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulator protein Activin E in primates for up to 8 weeks.
REGULATION | Jul 01, 2026, 02:38 PM UTC
L
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and t
EQUITY | Jul 01, 2026, 11:08 AM UTC